Abstract
A rat pneumonia model was established with a Pseudomonas aeruginosa strain that produced the plasmid-encoded metallocarbapenemase VIM-2. A significant decrease in lung bacterial titers was observed when imipenem, cefepime, ceftazidime, and piperacillin-tazobactam were given at the highest doses recommended for humans, despite their high MICs. Aztreonam at high doses produced a similar decrease in bacterial titers.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Bacterial Agents / pharmacokinetics
-
Anti-Bacterial Agents / therapeutic use*
-
Carbapenems / metabolism*
-
Drug Resistance
-
Injections, Intraperitoneal
-
Lung / microbiology
-
Lung / pathology
-
Male
-
Pneumonia, Bacterial / drug therapy*
-
Pneumonia, Bacterial / microbiology
-
Pneumonia, Bacterial / pathology
-
Pseudomonas Infections / diagnosis*
-
Pseudomonas Infections / microbiology
-
Pseudomonas Infections / pathology
-
Pseudomonas aeruginosa / drug effects*
-
Pseudomonas aeruginosa / enzymology
-
Rats
-
Rats, Wistar
-
beta-Lactamases / metabolism*
Substances
-
Anti-Bacterial Agents
-
Carbapenems
-
beta-Lactamases